(2002). AA: GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.
(2006). AA: The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy.
(2010). Ashby CR Jr: Inhibition of NAALADase by 2-PMPA attenuates cocaineinduced relapse in rats: a NAAG-mGluR2/3-mediated mechanism.
(2001). Assessment of cutaneous innervation by skin biopsies. Curr Opin Neurol
(2010). BS: Bioanalysis of NAAG as a Marker of GCP II Inhibition. Anal Biochem
(2002). BS: Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem
(2005). BS: Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.
(2008). Cavaletti G: Expression and distribution of ‘high affinity’ glutamate transporters
(2009). Cavaletti G: Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res
(1987). Coyle JT: Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain.
(1995). Coyle JT: N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system.
(1990). Coyle JT: Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization.
(2006). Danysz W: Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology
(2002). HL: Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain.
(1987). JH: Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia.
(2007). JH: Local administration of Nacetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats.
(2007). JW: Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies.
(1993). Neale JH: N-acetylaspartylglutamate catabolism is achieved by an enzyme on the cell surface of neurons and glia. Neuropeptides
(1999). PF: Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med
(2003). Roos RP: Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA
(2001). Slusher BS: Design of NAALADase inhibitors: a novel neuroprotective strategy. Curr Med Chem
(2004). The cloning and characterization of a second brain enzyme with NAAG peptidase activity.
(2005). The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci
(1999). The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther
(2008). Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate
(2005). VanGerven JM: The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol